Delving into the Latest Updates on Beijing Zhenzhi Medical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Other Diseases

Therapeutic vaccine

Cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Cell therapy	1
Therapeutic vaccine	1

主要目的 1）评价IPM001注射液治疗进展期原发性肝细胞癌患者的安全性和耐受性； 2）评估IPM001注射液的药代动力学（免疫动力学）特征； 3）确定IPM001注射液II期临床试验推荐剂量（RP2D）；次要目的 1）评估IPM001注射液治疗进展期原发性肝细胞癌的初步临床有效性。探索性目的 2）探索IPM001注射液诱导的免疫应答与临床疗效的相关性。

[Translation]

Main purpose 1) Evaluate the safety and tolerability of IPM001 injection in the treatment of patients with advanced primary hepatocellular carcinoma; 2) Evaluate the pharmacokinetic (immunokinetic) characteristics of IPM001 injection; 3) Determine the recommended dose (RP2D) for the Phase II clinical trial of IPM001 injection; Secondary purpose 1) Evaluate the preliminary clinical efficacy of IPM001 injection in the treatment of advanced primary hepatocellular carcinoma. Exploratory purpose 2) Explore the correlation between the immune response induced by IPM001 injection and clinical efficacy.

Start Date-

Sponsor / Collaborator

Beijing Zhenzhi Medical Technology Co., Ltd.Startup

NCT05536427

/ Unknown statusPhase 1IIT

An Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation and Dose-Expansion, Investigator-Initiated Phase I Clinical Study to Observe and Evaluate the Tolerability, Safety, Pharmacodynamics, and Preliminary Efficacy of IPM001 Injection in the Treatment of Progressive Hepatocellular Carcinoma

In this study, safety and effects of IPM001 injection on human hepatocellular carcinoma are going to be investigated, IPM001 is a multiple tumor-associated antigen (TAA) and neoantigen/tumor-specific antigen (TSA) sensitized autoimmune cell injection

Start Date01 Oct 2022

Sponsor / Collaborator

Peking Union Medical College Hospital

[+1]

NCT05105815

/ Not yet recruitingEarly Phase 1IIT

An Exploratory Study on the Safety and Effectiveness of Autoimmune Cell Therapy Sensitized With Liver Cancer Neoantigen in Patients With High Risk of Recurrence After Surgical Resection of Primary Hepatocellular Carcinoma

In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection

Start Date31 Dec 2021

Sponsor / Collaborator

Shanghai Huashan Hospital

[+2]

100 Clinical Results associated with Beijing Zhenzhi Medical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Zhenzhi Medical Technology Co., Ltd.

Login to view more data

100 Deals associated with Beijing Zhenzhi Medical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Zhenzhi Medical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

2

1

Other

Login to view more data